<DOC>
	<DOCNO>NCT01082315</DOCNO>
	<brief_summary>After consultation Korean Health Authorities , two Post-Authorization Safety Studies EMR 62202-509 ( NCT01082315 ) EMR 62241-508 ( NCT01075828 ) combine within one study protocol EMR 062202-551 . This Post-Marketing Surveillance Study ( PMS ) EMR 062202-551 requested Korean Health Authorities continue monitor Erbitux provide information safety toxicity clinical practice least 900 patient 6 year . All data point EMR 62202-509 ( NCT01082315 ) EMR 62241-508 ( NCT01075828 ) remain unchanged protocol EMR 062202-551 . Therefore , Sponsor decide separately disclose EMR 062202-551 study title `` A Korean Post-Marketing Surveillance Study On Erbitux® ( Cetuximab ) Patients With Locally Advanced Recurrent and/or Metastatic Squamous Cell Cancer Head Neck ( originally EMR 62241-508 ) Patients With EGFR-expressing , KRAS wild-type Metastatic Colorectal Cancer ( originally EMR 62202-509 ) '' clinicaltrials.gov .</brief_summary>
	<brief_title>A Korean Post-marketing Surveillance Study Erbitux® Patients With Metastatic Colorectal Cancer Refractory Irinotecan-containing Treatment</brief_title>
	<detailed_description>This post marketing surveillance ( PMS ) , prospective study collect safety information 600 subject epidermal growth factor receptor ( EGFR ) -expressing , V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog ( KRAS ) wild-type metastatic colorectal cancer ( mCRC ) treat Erbitux final evaluable case . This PMS request Korean Regulatory Authorities removal orphan drug Korea , requirement investigate 600 patient six year , continue monitor provide information safety toxicity clinical practice . This PMS study plan conduct within 6 year removal date orphan drug approximately 50 institution Korea . OBJECTIVES The objective study analyse safety efficacy information use Erbitux market factor affect safety efficacy . Primary objective : - To obtain safety information use Erbitux subject mCRC term frequency severity adverse event ( AEs ) Secondary objective : - To gather clinical efficacy information treatment During PMS period , subject 's background , medical history ( surgery , radiotherapy ) , Erbitux treatment status , concurrent medication , response evaluation , status reason discontinuation , AEs ( regardless causal relationship Erbitux ) , abnormal result laboratory test collect start treatment Erbitux progressive disease , Erbitux-related intolerable toxicity , death , withdrawal Erbitux treatment ( whichever occurs first ) . The primary endpoint , safety evaluation base case treat Erbitux receive least one dose . However , efficacy evaluation , 12 week treatment apply subject . Erbitux prescribe mCRC subject accord approve national label routine clinical practice , supervision investigator experience use antineoplastic medicinal product . Prior first infusion , subject receive pre-medication antihistamine corticosteroid . The initial dose Erbitux 400 mg/m2 body surface area subsequent weekly dos 250 mg/m2 administer intravenously via in-line filtration infusion pump , gravity drip , syringe pump . The recommended infusion period initial dose 120 minute subsequent weekly dos 60 minute maximum infusion rate exceed 10 mg/min , equivalent 5 ml/min Erbitux 2 mg/ml .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Subjects eligible Erbitux treatment accord indication national label Erbitux ( i.e . EGFR express , KRAS wildtype mCRC subject combination chemotherapy , single agent subject fail oxaliplatin irinotecan base therapy intolerant irinotecan ) Subjects eligible Erbitux treatment accord indication national label Erbitux</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Neoplasm metastasis</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Erbitux</keyword>
	<keyword>EGFR</keyword>
</DOC>